Dapagliflozin plus methylcobalamin improved nerve function and glucose control in diabetic neuropathy.

Dapagliflozin is a selective inhibitor of sodium–glucose cotransporter 2 (SGLT2) that blocks glucose resorption in the proximal tubule of the kidney and promotes glucosuria. 11-13 Other SGLT2 ...

Dapagliflozin was stopped for reasons other than death in 249 patients and placebo was stopped in 258 patients (10.5% vs. 10.9%, P=0.71). At the last assessment, ...

Dapagliflozin produces a dose-dependent and sustained reduction in both fasting and postprandial serum glucose levels through increased urinary glucose excretion, ...

Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Dapagliflozin 10 mg also resulted in greater weight loss than did metformin (P < .0001). Events suggestive of genital infection were reported in 6.7%, 6.9%, ...

In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk for CV death and worsening HF compared with placebo, with no attenuation of treatment ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney ...

Individuals treated with dapagliflozin demonstrated a reduction in FPG, a secondary endpoint, from baseline at week 24: -12.5 mg/dL for dapagliflozin 2.5 mg, -18.8 mg/dL for dapagliflozin 5 mg and ...